Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"INTELLIGENT PREDICTIONS!!!"
My gosh, what are you all drinking? - lol
Ann
Following is the Senecio/DNAP Grant we have wondered re: the outcome for some time:
http://www.askanywhere.com/news310105.html
Ann
DNAP exhibiting DNA Witness:
"We are extremely pleased to be exhibiting DNAWitness™ and other products at the IACP Conference, which draws 14,000 law enforcement officials from all over the world," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We look forward to demonstrating how DNAWitness™ can improve their crime scene investigations and enhance their forensic capabilities."
DNAWitness™ employs patent-pending, database-driven methods to infer elements of physical appearance from crime scene DNA and allow forensic investigators to "paint" molecular portraits of a suspect. This innovative forensic technology has already been used in some 130 cases, including the arrest and conviction of Derrick Todd Lee for a series of murders in Louisiana and in New Scotland Yard's search for the so-called Minstead Rapist, a serial sex offender who is operating in an area south of London.
DNAWitness™ derives the percentage of European, East Asian, Native American, and Sub-Saharan African markers in a person's DNA. This ratio for an individual is termed Bio-Geographical Ancestry (BGA), representing general characteristics that can be matched with a searchable database containing information and photographs collected from samples around the world, leading to more accurate identifications of potential criminal suspects.
Ann
DNAP presents DNAP Witness Retinome:
http://www.dnawitness.net/retinome.htm
Ann
Bag:
"Have you queried DNAG to see why they haven't updated their website to reflect Monica's departure, among other glaring things."
I have not.
Take care,
Ann
investigating
Apparently, it was a copter...of course, they're now investigation...
Ann
Froggy:
Oh, oh...a "Dear Ann" letter...
I went to an extreme in providing info from the 1st newsletter of DNAP co. news, not because I am unaware of past or current events or what DNAP's organization prospects have enolved into to the betterment of it's pipelines throughout the past six years, but, to simply point out a couple of very profound statements quoted by Tony regarding SNPS, because "that is what is currently under discussion." It is unaccesary for your casting me as naive or somewhat underachieved. Also, not neccasary for your kid-gloved approach of your rebuttal towards me.
Throughout these several patient years for us who have stuck it through, I have read and re-read your analyzations of investor exchanges vs. your negative slants and views, day in and day out with whichever poster you wished to duel - slaps in the face with your semi-glistening off-white glove and your never-ending "touches." Your psyche, bottom line: "You simply HAVE to have the last word!!"
Hence, I KNOW if my reply to you now isn't geared to your specifics and expectations, (confused yet?) I presume I will get a long dissertation post-provided. You may not want to waste your time, though. Sorry to dissapoint you, my friend, but, I AM totally aware of what goals DNAP is endeavoring, working towards, whether it ever is realized or not, all the way through the possibilities of not making it through all of the legal or financial burdens, etc. and etc. so, specifically, I will continue to judge what I post regarding potential investor-related DD., whether it passes your inspection or not.
We have a choice, Froggy. We can both be gazing at a similar object - I choose to look at most things with a positive outlook and approach, simply because that's how I wish to conduct my life............and.........you...........?
I do, however, may I add, Froggie, appreciate your somewhat catious demeanor towards me. What did I do to deserve that? - lol
Take care,
Ann
Dedicated to Froggy:...from the first co. newsletter: Of course, you'll analyze and discredit this as you do "everything" that comes your way...
"We have constructed a library of SNP maps, showing where, in genes, individual human beings differ from one another. Our maps are by far the best in the world. Due mainly to our proprietary (and patent pending) protocols, our SNP maps are deeper and more detailed than those held publicly (NCBI) or privately (such as at Celera, Affymetrix, Incyte, Human Genome Sciences and even Gennaissance). Furthermore, our maps cover the entire length of the gene in the genome. The maps being constructed by others are focused at the ends. This is a crucial point because the depth and breadth of the maps are important! You can think of them as “treasure maps” - the more detailed and accurate the map, the better your chance of finding the treasure. As an investor in DNAPrint genomics, you should feel proud that you own a piece of the most comprehensive and valuable pharmaco-relevant SNP library on the planet."
Ann
E-symposion Mission Statement:
"We were extremely pleased with the results of the first global e-Symposium on Ancestry, which attracted so many participants from so many places," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "Clearly, there is worldwide interest in exploring the scientific underpinnings of DNA research. We believe people are especially interested in DNA research to trace ancestry and identify individual characteristics that not only define personal identity but can also aid in the diagnosis and treatment of certain diseases. We hope that this is the first of many public forums into the mysteries and science of DNA sponsored by our Company."
Ann
Highlights of E-symposium presentations:
Highlights of e-Symposium presentations:
-- Gavin Menzies, author, "1421 - The Year China Discovered the World."
Descendants of Chinese crewmen who survived shipwrecks off the North Carolina and Virginia coast now are living in the Appalachian mountain area of the U.S. The first Europeans who came to North Carolina found Chinese artifacts.
-- Jason Eshelman, Senior Research Director, Trace Genetics, Inc, a DNAPrint subsidiary. Ancient DNA finds should be treated with skepticism.
A report about dinosaur DNA being recovered turned out to be human DNA. The sample was contaminated by those handling it. Always make certain that Ancient DNA analysis is done utilizing the proper protocols.
-- Edward Ball, author, "Genealogy & DNA Technology." An antique desk containing packets of hair locks, some 175 years old, initiated a quest to learn about Mr. Ball's family heritage, revealing family ties to Europe and the African country of Senegal.
-- Brian M. Kemp, Ph.D. candidate, Department of Anthropology, University of California, Davis. Evidence shows that the first humans entered the Americas approximately 15,000 years ago during a glacial period.
-- Jeff Long, Professor of Human Genetics and Adjunct Professor of Biostatics, University of Michigan. A primer on the genetic structure of populations and the difficulties inherent in distinguishing between and among races of humans.
-- Toomas Kivisild, Senior Scientist, Estonian Biocentre. Genetic variations in Asian and sub-Asian populations.
-- Tony N. Frudakis, Ph. D., Chief Scientific Officer, DNAPrint Genomics, Inc., a DNAPrint subsidiary. A discussion of the rich nature of DNA around the world and how Ancestry Information Markers (AIM) are playing a key role in the development of pharmaceuticals and forensic technologies.
Ann
An update on E-Symposium:
http://www.marketwire.com/mw/release_html_b1?release_id=146592
Ann
"The research will be conducted under the supervision of Dr Mark Froimowitz, a researcher at the Boston-based college, who recently licensed the compounds to DNAPrint Genomics."
Ann
Add this to DNAP's credits: (Novartis connection)
6th March 2006
By Staff Writer
"DNAPrint Genomics has revealed that it is to collaborate with the Massachusetts College of Pharmacy and Health Sciences on the potential development of Ritalin-like compounds as possible medications for drug abuse, ADHD and depression.
The compounds are analogs of Novartis' Ritalin, used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.
The research will be conducted under the supervision of Dr Mark Froimowitz, a researcher at the Boston-based college, who recently licensed the compounds to DNAPrint Genomics.
"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," stated DNAPrint chief medical officer Dr Hector Gomez. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."
Ann
Jever000:
OT:
"SOMETHING had BETTER Come Soon!!"
Ann
Dr. Dew:
"We need to get them this info"
Has been forwarded.
(P.S. I have forwarded it to DNAP. Hard to believe they aren't already aware, though, but, just in case, wink, wink)
Take care,
Ann
More:
DNAPrint's Forensic Research Accepted for Publication
SARASOTA, Fla., March 28 /PRNewswire/ --
DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) (DNAPrint or the
"Company"), the world leader in the measurement of genome structure for personalized medicine, qualitative forensics and consumer genomics, announced today that part of its work on Biogeographical Ancestry determination from DNA has been accepted for publication in the Journal of Forensic Sciences.
The manuscript describing this science successfully passed a peer-review process and will be published in an upcoming issue of the journal.
Biogeographical Ancestry (BGA) is the heritable component of race and DNAPrint is the first to have developed and patented methods for inferring BGA Admixture from DNA (http://www.ancestrybydna.com). Publication provides a means by
which other scientists and prospective customers can study and validate the Company's science. The manuscript, which is accepted for publication, describes merely one facet of the Company's method for BGA Admixture determination. It's the first in a series of papers the Company intends to publish on the topic.
About AncestrybyDNA
AncestrybyDNA 2.0 is the world's first genomics product for the inference of individual biogeographical ancestry (i.e. "race") admixture from DNA.
Unlike other tests of this type, DNAPrint uses genomics advances to "read" all 23 chapters of the chromosomal or genetic "book" contained in every cell of each human being. The product was recently featured in CBS Evening News' "Eye on America" with Dan Rather and the CBS Sunday morning show. For more information about the test, please visit http://www.ancestrybydna.com.
Ann
Do you think DNAP can accomplish this?
ARCHON X PRIZE FOR GENOMICS — LARGEST MEDICAL PRIZE IN HISTORY IS LAUNCHED
The X PRIZE Foundation announced today the $10 million Archon X PRIZE for Genomics —
A multi-million dollar incentive to create technology that can successfully map 100 human genomes in 10 days. The prize is designed to usher in a new era of personalized preventative medicine and stimulate new avenues of research and development of medical sciences."
Ann
Wow! A BIGGEE! Do you suppose DNAP is onto this one? $10 million offered to solve Genome Map
http://news.aol.com/topnews/articles/_a/new-10-million-x-prize-offered-for-fast/n2006100416550999001...
Just in case, I may e-mail this to DNAP -
Ann
Dr. Fru:
OT:
"I do hope all of your hopes, dreams and aspirations regarding DNAG come true."
Wouldn't that "finally" be something! - lol
Ann
OT:
You going back on your lilly pad, Froggy?
Ann
"We are currently preparing for a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) to discuss the preclinical studies for PT-401.
"Other therapies in our product pipeline include Ritalin(tm)-like compounds for the potential treatment of drug abuse, attention deficit hyperactivity disorder (ADHD), and depression," Dr. Gomez said. "These compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing the potential for cardiovascular complications, abuse and a patient's required daily dosage."
Ann
'06 Shareholder's meeting:
http://www.primezone.com/newsroom/news.html?d=101142
Ann
Don't recall this PR - but, even so, interesting to review:
http://www.marketwire.com/mw/release_html_b1?release_id=100496
Ann
News on DNAPrint Pharmaceuticals (has a nice ring to it):
http://www.biospace.com/news_company.aspx?CompanyID=1002228
Ann
Jever - this is DNAP's:
http://dnaconsultants.com/Detailed/12.html
Ann
Hey Jever:
DNA Testing by DNAP distributor:
http://www.genetree.com/ancestral/ancestryByDnaInfo.php
Ann
And this also as part of the DD: "DNAP receives Notice of Allowance..."
http://www.macreport.net/todaysMarkets.asp?id=2258
Ann
May I add this:
"DNAPrint gets patent for test that predicts effect of drugs 21 Sep 2006 11:54 GMT ... because they are the key to developing theranostic drugs. ..."
Ann
Sandoz:
I appreciate your request, though I am more of a fact poster than a discussor - lol. There are a few here that will probably be more than happy to engage with you in your important queeries.
I have been with DNAG since inception and, as many investors definitely know, this stock is undervalued. That's quite obvious at this point in time, but, with DNAP's pipeline, patents, etc., certainly and hopefully may eventually realize it's business plans. Looks as though we will have to wait and wait and wait to see the final outcome. It's like, "Now I know how Columbus felt when he saw land!" - lol
Take care, Sandoz,
Ann
Lastly, Dr. Fru:
"Richard Gabriel, CEO and President of DNAPrint said: “We are extremely excited about the alliance between DNAPrint and Biofrontera, and we believe we have established a reliable and trustworthy source of capital for the development of both companies. Our goal for this financing, once it is completed through the registration process, is to build shareholder value beyond the inherent investment value that Biofrontera brings to the relationship. We hope to increase revenues of both companies by combining the distinct businesses and by offering services that address many of the problems in drug discovery and development.”
Ann
And Dr. Fru:
"Improving the patient selection by DNAPrint's unique technology will render Biofrontera’s clinical trials less costly and expedite the development of our drugs. We consider the ability to predict the individual patient's response to our drugs an extremely valuable addition to our effort in serving the patients' needs. Rapid success in drug development will move Biofrontera towards its goal of an initial public offering.”
Ann
Dr. Fru:
I am also reminding you:
"Forming such a close alliance with a US company is a significant milestone for Biofrontera. It provides us with substantial resources we need to move our products ahead in clinical development, and to establish the key clinical milestones which will form the basis of the future value of Biofrontera”, commented Hermann Lübbert. “We are excited by the recent progress in developing our lead product BF-Derm1 for the treatment of severe chronic Urticaria, and the proceeds of this investment should enable us to bring this and other promising products to the market within the next three years."
Ann
Dr. Fru:
Didn't you go to church today?
Ann
A reminder:
"DNAPrint’s investment in Biofrontera is secured by a commitment from Dutchess Private Equities Fund to invest up to US $ 35 mln. in newly issued DNAPrint shares over the next two years. The funding will begin after the company registers the common stock that the company will issue in the transaction.
"Forming such a close alliance with a US company is a significant milestone for Biofrontera. It provides us with substantial resources we need to move our products ahead in clinical development, and to establish the key clinical milestones which will form the basis of the future value of Biofrontera”, commented Hermann Lübbert. “We are excited by the recent progress in developing our lead product BF-Derm1 for the treatment of severe chronic Urticaria, and the proceeds of this investment should enable us to bring this and other promising products to the market within the next three years.
Improving the patient selection by DNAPrint's unique technology will render Biofrontera’s clinical trials less costly and expedite the development of our drugs. We consider the ability to predict the individual patient's response to our drugs an extremely valuable addition to our effort in serving the patients' needs. Rapid success in drug development will move Biofrontera towards its goal of an initial public offering.”
Richard Gabriel, CEO and President of DNAPrint said: “We are extremely excited about the alliance between DNAPrint and Biofrontera, and we believe we have established a reliable and trustworthy source of capital for the development of both companies. Our goal for this financing, once it is completed through the registration process, is to build shareholder value beyond the inherent investment value that Biofrontera brings to the relationship. We hope to increase revenues of both companies by combining the distinct businesses and by offering services that address many of the problems in drug discovery and development.”
Ann
USMC:
"The more I see other companies getting into this game, the farther behind we get."
I don't totally agree. It would be naive to think that there is no competitive companies in this field of biotechnology. Obviously there is, but, in different applications, stages and degrees. "Success" is based on competition - (at least in the Good Ole USA) - We'll see, USMC - IMO
Take care,
Ann
Another:
Thank You!
Take care,
Ann
usmc:
I didn't write the article. Just posting it for your (lol) comments.
Take care,
Ann
Did anyone closely read the #50845 post?
Ann